Skip to main content
. 2024 Mar 20;8:100239. doi: 10.1016/j.jtauto.2024.100239

Fig. 3.

Fig. 3

The fluctuations of serum autoantibodies against sp100 in patients with PBC. A, anti-sp100 autoantibodies levels were initially lower and changed to negative or weakly positive after the initiation of UDCA treatment in four patients; B, anti-sp100 autoantibodies levels were sustained at a relatively high concentrations and consistently positive in 11 patients; C, one patient developed anti-sp100 autoantibodies during follow-up; D, Reactivity to sp100 protein of sequential serum samples in 3 representative PBC patients. Reactivity of patient NO.16 with stable anti-sp100 positivity; Reactivity of patient NO.17 who lost anti-sp100; Reactivity of patient NO.19 with increasing anti-sp100 concentrations; lane 1, sp100 protein (23 kDa), lane 2, BPO (approximately 55 kDa), lane 3, mHSA108, lane 4, PDC-E2 antigen containing outer and inner lipoyl domain (approximately 30 kDa). Reactivity to sp100 protein of more sequential serum samples were in supplementary materials.